Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient’s body to replace diseased or missing ones.
This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures.
Request a Sample Copy @ https://bit.ly/3mkJZTx
Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the industry for cell therapy.
Key Manufactuere for Cell Therapy Industry are: ALLOSOURCE, CELLS FOR CELLS, HOLOSTEM TERAPIE AVANZATE SRL, JCR PHARMACEUTICALS CO., LTD, KOLON TISSUEGENE, INC, MEDIPOST CO., LTD., MESOBLAST LTD., NUVASIVE, INC., OSIRIS THERAPEUTICS, INC., STEMEDICA CELL TECHNOLOGIES, INC.